Bangliang Li

Title: Bangliang Li: Innovator in Indole Derivatives

Introduction

Bangliang Li is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on indole derivatives. His research focuses on developing compounds that can effectively treat various autoimmune and inflammatory diseases.

Latest Patents

Bangliang Li holds a patent for an indole derivative and its application in drug development. The invention relates to a specific indole derivative represented by general formula (I-1). This compound is designed to prevent and treat conditions associated with S1P receptor-related disorders. The modified indole derivative exhibits excellent biological activity, making it an ideal S1P receptor regulator with high efficiency. The compounds derived from this formula can be utilized to address a range of health issues, including Crohn's disease, ulcerative colitis, psoriasis, rheumatoid arthritis, and multiple sclerosis, among others.

Career Highlights

Bangliang Li is currently associated with Shanghai Medicilon Inc., where he continues to advance his research and development efforts. His work has positioned him as a key figure in the pharmaceutical industry, particularly in the area of drug discovery and development.

Collaborations

He collaborates with notable colleagues, including Feng Ren and Yubin Lv, who contribute to his research initiatives and help drive innovation within the company.

Conclusion

Bangliang Li's contributions to the field of pharmaceuticals through his innovative indole derivatives highlight his commitment to addressing complex health challenges. His work not only showcases his expertise but also emphasizes the importance of collaboration in advancing medical science.